Evolent Health (EVH): which funds own it

Who owns Evolent Health?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Cadian Capital Management, 9.3% (13G filed May 15, 2025), BlackRock Portfolio Management, 5.5% (13G filed Jul 17, 2026) and Rubicon OP GP II, 5.2% (13G filed Nov 14, 2025). As of Jun 30, 2026, the largest holders reported on Form 13F were BlackRock (13.2% of the shares), Cadian Capital Management (9.6%) and Morgan Stanley (8.0%).

Sources:13G by Cadian Capital Management (May 15, 2025) ↗13G by BlackRock Portfolio Management (Jul 17, 2026) ↗13G by Rubicon OP GP II (Nov 14, 2025) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 1, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

• BlackRock14.8 MIndex manager · 13.10% of the company+3.9 M
• Cadian Capital Managementconcentrated10.8 MInvestment firm · 9.57% of the company0
• Morgan Stanley9.0 MBank or trading desk · 7.93% of the company−112 K
• UBS Group6.2 MBank or trading desk · 5.52% of the company−1.9 M
• Rubicon Founders5.8 MSingle-position portfolio · 5.14% of the company0
• Engaged Capitalconcentrated5.6 MType not verified · 4.92% of the company0
• D. E. Shaw5.1 MQuant or multi-manager · 4.52% of the company−326 K
• Vanguard Capital Management4.8 MIndex manager · 4.23% of the company−79 K
• Wace, Llp Marshall3.4 MInvestment firm · 3.02% of the company+2.6 M
• Nuveen3.1 MInvestment firm · 2.77% of the company+2.9 M

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 99.8% of the shares · top 10: 61.0% · in index firms: 28.0% of the institutional total

Shares reported by the 198 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (May 1, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Shares outstanding: buybacks and dilution

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

• Dec 2, 2025Routinefiling ↗

  Change in directors or officers (Item 5.02)

• Nov 6, 2025Routinefiling ↗

  Change in directors or officers (Item 5.02)

  «Evolent Announces Third Quarter 2025 Results»

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.